




**INTERNATIONAL
BREAST CANCER
CONGRESS
DUBLIN/SEPT27**



RCSI



IBCCDUBLIN.IE

IN PARTNERSHIP

ABS

ASSOCIATION OF
BREAST SURGERY

FÁILTE WELCOME

We are delighted to invite you to the International Breast Cancer Congress (IBCC 2027), hosted by RCSI, taking place at the Convention Centre Dublin (CCD) from 9-11 September 2027. IBCC 2027 will serve as a premier global forum for advancing breast cancer research, clinical practice, and patient care.

This multidisciplinary meeting will bring together leading oncologists, surgeons, radiologists, pathologists, researchers, and allied health professionals to share the latest evidence-based strategies and innovations. With expert-led sessions, cutting-edge science, and unparalleled networking opportunities, IBCC 2027 offers a unique chance to engage with global leaders, foster collaboration, and translate research into better outcomes for patients worldwide.

The call for abstracts will launch in October and we look forward to submissions for both oral and poster presentation.

Dublin provides the perfect backdrop for this important exchange of knowledge – a city celebrated for its culture, history, and warm hospitality.

We look forward to your participation in what promises to be an outstanding event.

Warm regards,

Professor Michael Kerin

President RCSI;

Chair of Surgery at the University of Galway;

Consultant General and Breast Surgeon at Galway University Hospital

Mr Michael Boland

Consultant Breast and Oncoplastic Breast Surgeon,
St Vincent's University Hospital, Dublin

Professor Janice Walshe

UCD Clinical Professor

Consultant Medical Oncologist

Medical Oncology Department

St Vincent's University Hospital

WEDNESDAY, 8 SEPTEMBER 2027
RCSI, 118 ST STEPHEN'S GREEN, DUBLIN 2

PRE-MEETING SYMPOSIA



RCSI, 123 ST STEPHEN'S GREEN, DUBLIN 2



RCSI, 26 YORK STREET, DUBLIN 2





**LEADING
THE WORLD
TO BETTER
HEALTH**

DAY ONE

THURSDAY, 9 SEPTEMBER 2027

All Day	Registration, Foyer, Ground Floor, CCD
Morning	Pre-Congress Workshops
15.00	WELCOME ADDRESS Modern Breast Cancer Management - Lessons Learned Professor Michael J Kerin, President RCSI
15.15	SESSION 1 - COMBINED SESSION Debate 1 In the era of personalised medicine is traditional breast cancer trial design still relevant? Debate 2 TBC
16.55	<i>Break and visit the exhibition</i>
17.20	Introduction of Keynote
17.30	KEYNOTE LECTURE Increasing Role of Circulating Tumor DNA in Breast Care Management
18.50	Welcome Reception

DAY TWO

FRIDAY, 10 SEPTEMBER 2027

CONVENTION CENTRE DUBLIN (CCD),
SPENCER DOCK NORTH WALL QUAY DUBLIN 1 D01 T1W6

07.30 - 08.30	Morning Symposia	
08.30 - 10.00	SESSION 2 - PARALLEL SESSION	
	Parallel: Breast Pathology for the Surgeon	Parallel: Emerging Therapy Strategies in ER+ HER- Breast Cancer
	Subtype of Triple Negative breast cancer - a more personalised approach to therapy	Med Onc – Emerging Strategies in ER+ HER- breast cancer premenopausal
	TBC	Should all new patients with ER+ disease be offered oral SERDs?
	TBC	Should all patients with intermediate risk ER+ HER- breast cancer receive adjuvant CDK inhibitors?
		Should all young women receive ovarian suppression as part of treatment for breast cancer?
10.00 - 10.30	Break and visit the exhibition	

DAY TWO FRIDAY, 10 SEPTEMBER 2027

10.30 - 12.15	SESSION 3 - PARALLEL SESSION Parallel: Management of the Axilla ALND and TAD in the primary surgery setting - What is the evidence? ALND is necessary after NACT in node positive patients? Omission of Sentinel Node Biopsy in Early Breast Cancer Yes or No?		Parallel: Systemic Therapy Does Anthracycline have a place in the treatment of ER +, HER-2 negative breast cancer? Are new therapies replacing traditional regimes for ER+ disease? Should all ER+, HER-2 negative receive immunotherapy?
12.15 - 13.15	<i>Lunch and visit the exhibition</i>		
13.15 - 14.15	SESSION 4 - COMBINED SESSION Top Papers of 2026 and 2027: An Overview of What is New Surgical 30 minutes and Medical Oncology 30 minutes		
14.30 - 15.45	SESSION 5 - PARALLEL SESSION Parallel: DCIS Radiotherapy is no longer the standard of care for DCIS Is Surgery required for all DCIS? Decision making algorithms for adjuvant therapies DCIS		Parallel: Management of HER-2 Low Disease HER-2 low cancer is a misclassification and has no therapeutic strategy Defining HER-2 low disease pathology Drugs sequencing in HER-2 low breast cancer
15.45 - 16.15	<i>Break and visit the exhibition</i>		

16.15 - 18.00	SESSION 6 - PARALLEL SESSION	
	Parallel: Innovation	Parallel: Metastatic Disease
	All patients being offered a mastectomy should have access to a robotic procedure. Yes or No?	Should all patients with metastatic breast cancer undergo somatic gene analysis?
	Breast Conserving Surgery for Multifocal Disease Yes or No?	Treatment beyond CDK inhibition in ER+ metastatic breast cancer?
	Role of Lymphodema Surgery in Breast Cancer Patients	Drug sequencing in metastatic HER2 positive breast cancer
		Should all young women receive ovarian suppression as part of treatment for breast cancer?



DAY THREE

SATURDAY, 11 SEPTEMBER 2027



07.30 - 08.30	Morning Symposia	
08.30 - 09.30	SESSION 7 - PLENARY SESSION	
	(Oral presentations from submitted abstracts)	
09.30 - 10.30	SESSION 8 - PARALLEL SESSION	
	Parallel: Update on Surgical Trials	Parallel: Survivorship
	TBC	Pregnancy after breast cancer, is it safe?
		The role of HRT after breast cancer
		Risk Modification

DAY THREE SATURDAY, 11 SEPTEMBER 2027

10.30 - 11.00	<i>Break and visit the exhibition</i>
11.00 - 12.45	SESSION 9 - COMBINED SESSION Lobular Breast Cancer TBC TBC TBC TBC
12.45 - 13.45	<i>Lunch and visit the exhibition</i>
13.45 - 15.30	SESSION 10 - COMBINED SESSION Genetics and High Risk Screening - AI/Risk Prediction - Update on Prediction Models Debate 1 Should all patients with breast cancer have routine germline genetic panel testing? Debate 2 All patients with high risk penetrance genes should be offered Breast Conserving Therapy?
15.30	<i>Close of Congress</i>

CURRENT FACULTY

Dr Judy Boughey M.D.,

Professor of Surgery, Surgical Oncologist & Specialist Breast Surgeon
Mayo Institute

Dr Andreas Karakatsanis,

Breast Surgeon, Department of Surgical Sciences, Uppsala Universitet

Professor Bruce Mann,

Surgical Oncologist and Specialist Breast Surgeon; Professor of Surgery, University of Melbourne

Professor Stuart McIntosh,

Consultant Breast Surgeon, Professor of Surgical Oncology Queens University Belfast

Dr Ruth O'Regan,

Medical Oncologist, Chair of Medicine at the University of Rochester Medical Center (URMC)

Professor Carlo Palmieri,

Consultant Medical Oncologist & Clinical Scientist, Clatterbridge Cancer Centre

Professor Shelley Potter,

Professor of Surgical Oncology, University of Bristol

Ms Claire Rutherford,

Consultant Oncoplastic Breast Surgeon, St. Vincent's University Hospital, Dublin

Dr Paul Thiruchelvam,

Consultant Oncoplastic Breast Surgeon, Imperial College Healthcare

Professor Alastair Thompson,

Surgical Oncologist and Specialist Breast Surgeon;
Section Chief, Breast Surgery, Baylor College of Medicine

Ms Siún Walsh,

Consultant Breast Surgeon, Mater Misericordiae University Hospital, Dublin

Professor Walter Weber,

Medical Oncologist, University of Basel, Switzerland

Dr Anna Weiss M.D.,

Associate Professor of Surgery, Specialist Breast Surgeon, University Rochester Medicine

Professor Lynda Wyld,

Consultant Oncoplastic Breast Surgeon, Sheffield University

IBCCDUBLIN.IE



RCSI

UNIVERSITY
OF MEDICINE
AND HEALTH
SCIENCES

RCSI Ollscoil an Leighis agus na hEolaíochtaí Sláinte

www.rcsi.com